Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer

Abstract

The combination Pan-PI3K inhibition and ICB has significant antitumor effects in aUC with or without activated PI3K pathway and warrants further clinical investigation. This combination creates an immunostimulatory tumor milieu. Secondary resistance is associated with upregulation of the mTOR pathway and <i>Sprr</i> family genes.